Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Nature Communications|October 28, 2025
DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasmsBenjamin Goeppert, Alphonse Charbel, Reka Toth, et al.
The Journal of Pathology|July 26, 2020
miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axisMoritz A Loeffler, Jun Hu, Martina Kirchner, et al.
BMC Cancer|October 7, 2021
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinomaMarcell Tóth, Lilija Wehling, Lena Thiess, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO studyArndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Molecular & Cellular Proteomics : MCP|July 23, 2025
Accurate MS-Based Diagnostic Amyloid Typing Using Endogenously Normalized Protein Intensities in Formalin-Fixed Paraffin-Embedded TissueVanessa Hollfoth, Arslan Ali, Eyyub Bag, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 6, 2026
Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver CarcinogenesisSarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, et al.
Medicine|March 10, 2020
Expanding pancreas donor pool by evaluation of unallocated organs after brain death: Study protocol clinical trial (SPIRIT Compliant)Yakup Kulu, Elias Khajeh, Omid Ghamarnejad, et al.
Hepatology Communications|July 5, 2024
Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitisMarit M Grimsrud, Michael Forster, Benjamin Goeppert, et al.
Medicine|January 15, 2016
Loss of BAP1 Expression Occurs Frequently in Intrahepatic CholangiocarcinomaJuliana Andrici, Benjamin Goeppert, Loretta Sioson, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Pageof 14